Conferences - Results from #9960

Viewing 9961-9980 of 11775 articles

AUA 2016: Long-term follow-up circulating tumor cells as predictors for survival in men treated with abiraterone acetate for castration resistant prostate cancer following chemotherapy - Session Highlights

AUA 2016: Gene Expression Analysis of Bone Metastasis and Circulating Tumor Cells from Metastatic Castrate-resistant Prostate Cancer Patients - Session Highlights

AUA 2016: Galeterone shows anti-tumor activity in multiple pre-clinical models that express androgen receptor splice variants, supporting correlative patient data seen in ARMOR2 - Session Highlights

AUA 2016: Long-term safety and antitumor activity of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients from the ARADES and the ARAFOR trials - Session Highlights

AUA 2016: Defining Deliverables of Multiparametric Magnetic Resonance Imaging (mpMRI)/Ultrasound (US) Fusion-Guided Targeted Prostate Biopsy: Actionable Intelligence Metric (AIM) and Reduction Metric (RM) - Session Highlights

AUA 2016: Relationship of Post-operative Chronic Kidney Disease Subtype Status and Outcomes in Patients Undergoing Renal Surgery - Session Highlights

AUA 2016: Impact of Abiraterone Acetate in Prostate Specific AntiGEN Trial Update: Effect of abiraterone acetate and low dose prednisone on prostate-specific antigen and radiographic disease progression in patients with nmCRPC

AUA 2016: Study of PSMA-Targeted 18F-DCFPyL PET/CT in the Evaluation of Men with an Elevated PSA Following Radical Prostatectomy - Session Highlights

AUA 2016: Radium-223 re-treatment: Experience from an international, multicenter, prospective study in patients with castration-resistant prostate cancer and bone metastases - Session Highlights

AUA 2016: Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer - Session Highlights

AUA 2016: Case Discussion - Non-Metastatic and Asymptomatic Metastatic Castrate Resistant Prostate Cancer - Session Highlights

AUA 2016: What’s Next for Radiation Therapy in Low to Favorable/Intermediate Risk? - Session Highlights

AUA 2016: Ablation Therapy: How To Distinguish Oncologic Efficacy from an Active Surveillance Mimic - Session Highlights

AUA 2016: Lifestyle – Modifiable Risk Factors in Urology

AUA 2016: Eye of the Beholder: Is Delayed Treatment on Active Surveillance a Success or Failure? - Session Highlights

AUA 2016: Bladder Management after Spinal Cord Injury - Study Opportunity

AUA 2016: Studies Show Oral Testosterone Safe and Efficacious in Long-term Management of Hypogonadism

AUA 2016: Studies Demonstrate New Options to Help Prevent and Treat Nocturia

Convective Heat System Preserves Sexual Function While Treating LUTS and BPH

AUA 2016: Repeat Biopsy: State-of-the-Art Patient Selection and Technique - Session Highlights

494
495
496
497
498
499
500
501
502
503